Cystatin C assay, 1/16
January 2016—Beckman Coulter Diagnostics launched its Cystatin C assay for the company’s AU clinical low- to ultra-high-volume family of chemistry systems and Immage 800 immunochemistry systems.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Expanded enzyme offering, 1/16
January 2016—Worthington Biochemical announced distribution rights to the Celase GMP compliant enzyme from Cytori Therapeutics. The Celase GMP product offering allows Worthington customers focused on cell isolation studies to facilitate a smooth transition from bench and animal research to downstream clinical applications.
Oncology assays, 1/16
January 2016—Agena Bioscience announced the planned commercial launch of its CE-IVD marked MassArray Dx Plus assays for gene-specific mutation testing to aid in the selection of targeted therapy regimens. Agena Bioscience will introduce the first diagnostic kits in partnership with Diatech Pharmacogenetics.
NGS service for bacterial infection monitoring , 1/16
January 2016—BioMérieux and Illumina announced the launch of BioMérieux EpiSeq, a next-generation sequencing service dedicated to the epidemiological monitoring and control of health care–associated infections. The EpiSeq service is the first result of the collaboration agreement signed by the two companies in November 2014.
HSV assay and molecular diagnostics platform, 12/15
December 2015—Luminex received FDA clearance for its Aries System and Aries HSV 1&2 Assay. Aries is a sample-to-answer molecular diagnostics platform designed to increase laboratory efficiency, ensure result accuracy, and fit into a lean laboratory environment.
Arkray awarded urinalysis agreement, 12/15
December 2015—U.S. Arkray has been awarded a three-year agreement for automated urinalysis with Novation.
14-day hepatotoxicity testing, 12/15
December 2015—InSphero has launched a 14-Day Hepatotoxicity Testing Service designed to meet increased demand for contract screening in its patent-pending 3D InSight Human Liver Microtissues. The service streamlines toxicity testing of compounds in InSphero’s 3-D liver microtissues by initiating regular screening runs on the first Tuesday of each month, at $990 per compound.
Touchscreen grossing station, 12/15
Mopec introduced the Mopec MB800 touchscreen grossing station. Its interactive touchscreen display, which highlights essential grossing station operational information, monitors formalin level, bio waste level, filter usage duration, and ventilation performance. The high-output, touch-free LED lighting system permits adjustments in color and intensity and uniformly illuminates the dissection space, which offers interchangeable grid plates and cutting board surface options.
FDA-approved viral load tests, 12/15
December 2015—Roche received FDA approval for the Cobas HBV and Cobas HCV viral load tests for use on the Cobas 6800 and Cobas 8800 systems. Cobas HBV is a real-time PCR test designed to offer an expanded linear range coupled with broad coverage of all known HBV genotypes (A–H), including pre-core mutations with improved sensitivity.
Tissue array, 12/15
December 2015—Leavitt Medical’s tissue array, BxChip, allows six needle core specimens to be placed in one block, enabling labs to reduce slide production by one-sixth. Labs that use BxChip find significant savings in the technical component.